1. Home
  2. SCOR vs IPHA Comparison

SCOR vs IPHA Comparison

Compare SCOR & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo comScore Inc.

SCOR

comScore Inc.

N/A

Current Price

$7.31

Market Cap

112.4M

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.49

Market Cap

131.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SCOR
IPHA
Founded
1999
1999
Country
United States
France
Employees
N/A
163
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.4M
131.4M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
SCOR
IPHA
Price
$7.31
$1.49
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
12.7K
22.6K
Earning Date
05-05-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
127.37
N/A
EPS
4.25
N/A
Revenue
$403,549,000.00
N/A
Revenue This Year
$2.75
$180.36
Revenue Next Year
$7.30
N/A
P/E Ratio
$1.73
N/A
Revenue Growth
1.02
N/A
52 Week Low
$4.39
$1.18
52 Week High
$10.18
$2.63

Technical Indicators

Market Signals
Indicator
SCOR
IPHA
Relative Strength Index (RSI) 44.36 45.03
Support Level $6.28 $1.35
Resistance Level $7.18 $1.80
Average True Range (ATR) 0.54 0.08
MACD -0.06 -0.00
Stochastic Oscillator 16.35 10.00

Price Performance

Historical Comparison
SCOR
IPHA

About SCOR comScore Inc.

comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: